From Wikipedia, the free encyclopedia
|(what is this?)|
Carlumab is a human monoclonal antibody designed for oncology and immune indications.
Carlumab was developed by Johnson & Johnson.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Carlumab". American Medical Association.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|